Abstract
Esophageal adenocarcinoma in patients 45 years of age or younger is uncommon. We reviewed our experience with the surgical management of these patients to determine their clinical characteristics, pathologic findings, and treatment results. Thirty-two patients were identified through our surgical pathology database, and their medical records were reviewed to determine clinical characteristics, treatment, treatment-associated mortality, tumor staging, presence of Barrett’s mucosa, and survival. In our series, patients were white (100%) males (96.9%) with a history of reflux (56.3%), cigarette smoking (40.6%), and alcohol consumption (59.4%), who presented with progressive solid food dysphagia (78.1 %). A prior diagnosis of Barrett’s mucosa or use of antireflux medications was noted in five patients each (15.6%). There were no operative deaths. Actuarial survival was 81.1% (95% confidence interval [CI] 66.1 to 96.2) at 12 months, 68.5% (95% CI 49.5 to 87.5) at 24 months, and 56.9% (95% CI 34.6 to 79.1) at 60 months. Our findings show that patients with esophageal adenocarcinoma 45 years of age or younger have similar clinical findings to those reported in other large series where the median age is in the sixth or seventh decade of life, supporting a uniform theory of tumor pathogenesis. Esophagectomy may be performed with low mortality, and survival is reasonable for early-stage disease. Young patients with Barrett’s esophagus are not immune from the development of adenocarcinoma and need to be screened accordingly.
Similar content being viewed by others
References
Heitmiller RF, Sharma RR. Comparison of prevalence and resection rates in patients with esophageal squamous cell carcinoma and adenocarcinoma. J Thorac Cardiovasc Surg 1996; 112:130–136.
Hameeteman W, Tytgaf GNJ, Houthoff HJ, van den Tweel JG. Barrett’s esophagus: Development of dysplasia and adenocarcinoma. Gastroenterology 1989;96:1249–1256.
Reid BJ, Blount PL, Rubin CE, Levine DS, Haggitt RC, Ra-binovitch PS. Flow cytometric and histological progression to malignancy in Barrett’s esophagus: Prospective endoscopic surveillance of a cohort. Gastroenterology 1992;102:1212–1219.
Washington K, Chiappori A, Hamilton K, Shyr Y, Blanke C, Johnson D, Sawyers J, Beauchamp D. Expression of betacatenin, alpha-catenin, and E-cadherin in Barrett’s esophagus and esophageal adenocarcinomas. Mod Pathol 1998;11:805–813.
Mendes de Almeida JC, Chaves P, Pereira AD, Altorki NK. Is Barrett’s esophagus the precursor of most adenocarcinomas of the esophagus and cardia? A biochemical study. Ann Surg 1997;226:725–733.
Falk GW. Endoscopic surveillance of Barrett’s esophagus: Risk stratification and cancer risk. Gastrointest Endosc 1999;49:S29-S34.
Menke-Pluymers MB, Hop WC, Dees J, van Blankenstein M, Tilanus HW. Risk factors for the development of an adenocarcinoma in columnar-lined (Barrett’s) esophagus: The Rotterdam Esophageal Tumor Study Group. Cancer 1993;72:1155–1158.
Miros M, Kerlin P, Walker N. Only patients with dysplasia progress to adenocarcinoma in Barrett’s esophagus. Gut 1991; 32:1441–1446.
Wu TT, Watanabe T, Heitmiller RF, et al.. Genetic alterations in Barrett esophagus and adenocarcinoma of the esophagus and esophagogastric junction region. Am J Pathol 1998;153:287–294.
Salazar JW, Doty JR, Lin JW, Dyke MC, Roberts J, Heit-miller ES, Heitmiller RF. Does cell type influence post-esophagectomy survival in patients with esophageal cancer? Dis Esoph 1998;11:168–171.
Siewert JR, Feith M, Werner M, Stein HJ. Adenocarcinoma of the esophagogastric junction. Ann Surg 2000;232:353–361.
Heitmiller RF. Results of standard left thoracoabdominal esophagogastrectomy. Semin Thorac Cardiovasc Surg 1992;4:314–319.
Heitmiller RE. Esophageal tumors. In Cameron JL, ed. Current Surgical Therapy, 5th ed. St. Louis: Mosby, 1995, pp 45–49.
American Joint Committee on Cancer. Manual for Staging of Cancer, 3rd ed. Philadelphia: JB Lippincott, 1988.
Peto J, Seidman H, Selikoff IJ. Mesothelioma mortality in asbestos workers: Implications for models of carcinogenesis and risk assessment. Br J Cancer 1982;45:124–135.
Heitmiller RF, Forastiere AA, Kleinberg L, Zahurak M. Neoadjuvant chemoradiation followed by surgery for resectable esophageal cancer. Recent Results Cancer Res 2000; 155:97–104.
Hassall E, Dimmick JE, Magee JE. Adenocarcinoma in childhood Barrett’s esophagus: Case documentation and the need for surveillance in children. Am J Gastroenterol 1993;88:282–288.
Hassall E. Columnar-lined esophagus in children. Gastroenterol Clin 1997;26:533–548.
Cameron AJ, Lomboy CT. Barrett’s esophagus: Age prevalence, and extent of columnar epithelium. Gastroenterology 1992;103:1241–1245.
Sarr MG, Hamilton SR, Marrone GC, Cameron JL. Barrett’s esophagus: Its prevalence and association with adenocarcinoma in patients with symptoms of gastroesophageal reflux. Am J Surg 1985;149:187–193.
Sabel MS, Pastore K, Toon H, Smith JL. Adenocarcinoma of the esophagus with and without Barrett mucosa. Arch Surg 2000;135:831–835.
Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastrointestinal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999;340:825–831.
Falk GW. Reflux disease and Barrett’s esophagus. Endoscopy 1999;31:9–16.
Author information
Authors and Affiliations
Additional information
Supported by the Lawrence Katz Thoracic Surgery Award.
Rights and permissions
About this article
Cite this article
Scott Bolton, J., Wu, TT., Yeo, C.J. et al. Esophagectomy for adenocarcinoma in patients 45 years of age and younger. J Gastrointest Surg 5, 620–625 (2001). https://doi.org/10.1016/S1091-255X(01)80104-9
Issue Date:
DOI: https://doi.org/10.1016/S1091-255X(01)80104-9